In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions

Drug Metabolism and Drug Interactions

Volumn 21, Issue 3-4, 2006, Pages 187-211

  Hasselstøm, Jørgen ^a   Linnet, Kristian ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Drug drug interactions; Metabolism; Quetiapine; Substrate depletion

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ERYTHROMYCIN; HALOPERIDOL; KETOCONAZOLE; METHADONE; MEVINOLIN; NEFAZODONE; ORPHENADRINE; PERPHENAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; QUINIDINE; SIMVASTATIN; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DEPLETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; KINETICS; LIVER MICROSOME; MASS SPECTROMETRY; METABOLITE; QUANTITATIVE ANALYSIS;

ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; CYTOSOL; DIBENZOTHIAZEPINES; DNA, CIRCULAR; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KETOCONAZOLE; MASS SPECTROMETRY; MICROSOMES, LIVER; QUINIDINE;

EID: 33745668220     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993; 112: 285-292.
2. Hirsch SR, Link CG, Goldstein JM, Arvanitis LA. ICI 204,636: a new atypical antipsychotic drug. Br J Psychiatry Suppl 1996; 168: 45-56
3. Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001; 11: 415-424.
4. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40: 509-522.
5. Lin SN, Chang Y, Moody DE, Foltz RL. A liquid chromatographic- electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol 2004; 28: 443-448.
6. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006; 61: 58-69.
7. Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit 2004; 26: 486-491.
8. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001; 29: 1316-1324.
9. Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 2003; 31: 580-588.
10. Bousquet-Melou A, Laffont CM, Laroute V, Toutain PL. Modelling the loss of metabolic capacities of cultured hepatocytes: application to measurement of Michaelis-Menten kinetic parameters in in vitro systems. Xenobiotica 2002; 32: 895-906.
11. Obach RS, Reed-Hagen AE. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 2002; 30: 831-837.
12. Carlile DJ, Stevens AJ, Ashforth EI, Waghela D, Houston JB. In vivo clearance of ethoxycoumarin and its prediction from in vitro systems. Use of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes. Drug Metab Dispos 1998; 26: 216-221.
13. Suzuki A, Iida I, Tanaka F, et al. Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Drug Metab Dispos 1999; 27: 1254-1259.
14. Furuta S, Akagawa N, Kamada E, et al. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential. Br J Clin Pharmacol 2002; 54: 295-303.
15. Oda Y, Hamaoka N, Hiroi T, et al. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 2001; 51: 281-285.
16. Svensson US, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 1999; 48: 528-535.
17. Hopenwasser J, Mozayani A, Danielson TJ, et al. Postmortem distribution of the novel antipsychotic drug quetiapine. J Anal Toxicol 2004; 28: 264-267.
18. Zhou S, Chan E, Lim LY, et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004; 5: 415-442.
19. Li KY, Cheng ZN, Li X, et al. Simultaneous determination of quetiapine and three metabolites in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. Acta Pharmacol Sin 2004; 25: 110-114.
20. Li KY, Li X, Cheng ZN, Li HD. Metabolic mechanism of quetiapine in vivo with clinical therapeutic dose. Meth Find Exp Clin Pharmacol 2005; 27: 83-86.
21. Suzuki A, Iida I, Hirota M, et al. CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metab Pharmacokinet 2003; 18: 104-113.
22. Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002; 22: 174-182.
23. Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002; 22: 121-130.
24. Li KY, Li X, Cheng ZN, Zhang BK, Peng WX, Li HD. Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia. Eur J Clin Pharmacol 2005; 60: 791-795.
25. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987; 31: 1874-1878.
26. Laroudie C, Salazar DE, Cosson JP, et al. Pharmacokinetic evaluation of coadministration of nefazodone and lithium in healthy subjects. Eur J Clin Pharmacol 1999; 54: 923-928.
27. th Ed. Foster City, CA: Chemical Toxicology Institute, 1995.
28. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44: 1054-1062.
29. Segel IH. Enzyme kinetics. Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. New York: John Wiley & Sons, Inc., 1975.
30. Jones HM, Houston JB. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 2004; 32: 973-982.